Robert Schaub, Ph.D. is Chief Scientific Officer. Dr. Schaub has 35 years of experience in both academic and industrial research. This includes The University of Tennessee, Knoxville and the Upjohn Company where he was involved with the development of both the protein bio therapeutics program and small molecule agents. In 1990 he started a 17 year career at Genetics Institute/Wyeth in Cambridge, MA. The groups he led supported the marketing approval for factor IX (BeneFIX®); Interleukin-11 (Neumega®); and B-domain deleted factor VIII (ReFacto®) as well as preclinical support for protein and small molecule drugs that entered development for thrombosis, bone growth, oncology, inflammation and infectious disease. In 2006 he joined the Archemix Corp as VP of Preclinical Discovery and in 2009 became Sr. VP R&D. During this time the anti-von Willebrand aptamer ARC1779 entered and completed Phase I and entered Phase II. A P-selectin antagonist aptamer for the treatment of sickle cell disease reached Development stage and a program to develop aptamers for the treatment of hemophilia was initiated. A specific antagonist of the tissue factor pathway inhibitor for the treatment of hemophilia entered clinical development and was acquired by Baxter in 2010. Dr. Schaub obtained his B.S. from the University of Nevada and his Ph.D. from Washington State University. He received a Heart Association Postdoctoral Fellowship (WSU) and an NIH Postdoctoral Fellowship (Temple Medical School). He has been author/co-author on over 140 peer reviewed papers. He is a Fellow of the American Heart Association, the American Physiological Society and a member of several other scientific organizations including the American Society of Hematology. He is Adjunct Professor of Pharmacology at Boston University and on the editorial advisory board of Biochemical Pharmacology.  

NKT based therapeutics targeting NKT cells to treat sickle cell disease, autoimmune and inflammatory diseases, cancer, and asthma